BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)
BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
ADT Inc. (NYSE – ADT)
Under the terms of the Merger Agreement, ADT will be acquired by Thrive Holdings. Under the terms of the agreement, ADT shareholders will receive $10.00 per share in cash, in a transaction with an enterprise value of approximately $15.3 billion. The investigation concerns whether the ADT Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/adt-inc-nyse-adt/.
RXO Inc. (NYSE – RXO)
Under the terms of the Merger Agreement, RXO will be acquired by C.H. Robinson Worldwide, Inc. (Nasdaq – CHRW) in a stock-and-cash transaction where RXO stockholders will receive $17.25 per share in cash and 0.0856 shares of C.H. Robinson common stock for each RXO share they own, representing an implied total consideration of $30.25 per share, and an implied value of $5.8 billion. The investigation concerns whether the RXO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/rxo-inc-nyse-rxo/.
PTC Inc. (Nasdaq – PTC)
Under the terms of the Merger Agreement, PTC will be acquired by Schneider Electric for $205.00 per share in cash, an implied enterprise value of $23.7 billion. The investigation concerns whether the PTC Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/ptc-inc-nasdaq-ptc/.
Lifecore Biomedical, Inc. (Nasdaq – LFCR)
Under the terms of the Merger Agreement, Lifecore Biomedical will be acquired by Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value right (CVR) per share. The investigation concerns whether the Lifecore Biomedical Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/lifecore-biomedical-inc-nasdaq-lfcr/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. The News Headliner takes no editorial responsibility for the same.